1. Home
  2. Analysis
  3. Levothyroxine-sodium
  4. Bladder-transitional-cell-carcinoma

Levothyroxine sodium and Bladder transitional cell carcinoma - a phase IV clinical study of FDA data

Summary:

Bladder transitional cell carcinoma is reported as a side effect among people who take Levothyroxine sodium (levothyroxine sodium), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Prednisolone, and have High blood pressure.

The phase IV clinical study analyzes which people have Bladder transitional cell carcinoma when taking Levothyroxine sodium. It is created by eHealthMe based on reports of 122,907 people who have side effects when taking Levothyroxine sodium from the FDA, and is updated regularly.

What is Levothyroxine sodium?

Levothyroxine sodium has active ingredients of levothyroxine sodium. It is often used in hypothyroidism. eHealthMe is studying from 129,814 Levothyroxine sodium users. Check the latest studies of Levothyroxine sodium.

What is Bladder transitional cell carcinoma?

Bladder transitional cell carcinoma (types of bladder cancer) is found to be associated with 200 drugs and 229 conditions by eHealthMe. Check the latest studies of Bladder transitional cell carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

122,907 people reported to have side effects when taking Levothyroxine sodium.
Among them, 39 people (0.03%) have Bladder transitional cell carcinoma.

Could Levothyroxine sodium cause Bladder transitional cell carcinoma?

Among these 39 people:

How long have people been on Levothyroxine sodium when they have Bladder transitional cell carcinoma? *

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 100 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Bladder transitional cell carcinoma when taking Levothyroxine sodium? *

  • female: 89.47 %
  • male: 10.53 %

What is the age of people who have Bladder transitional cell carcinoma when taking Levothyroxine sodium? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 3.03 %
  • 60+: 96.97 %

What are other drugs people take besides Levothyroxine sodium? *

  1. Valsartan: 29 people, 74.36%
  2. Prednisolone: 29 people, 74.36%
  3. Nystatin: 28 people, 71.79%
  4. Ibuprofen: 28 people, 71.79%
  5. Ciprofloxacin Hydrochloride: 28 people, 71.79%
  6. Minoxidil: 28 people, 71.79%
  7. Azithromycin: 27 people, 69.23%
  8. Rasilez: 26 people, 66.67%
  9. Fluconazole: 26 people, 66.67%
  10. Fosfomycin Tromethamine: 26 people, 66.67%

What are other side effects people have besides Bladder transitional cell carcinoma? *

  1. Second Primary Malignancy (after getting cure a cancer, a new cancer development): 4 people, 10.26%
  2. Ureteric Cancer: 2 people, 5.13%
  3. Neoplasm Malignant (cancer tumour): 2 people, 5.13%
  4. Weight Increased: 1 person, 2.56%
  5. Impaired Work Ability: 1 person, 2.56%
  6. Anaemia (lack of blood): 1 person, 2.56%
  7. Arthritis Bacterial (form of joint disorder that involves inflammation of one or more joints due to bacterial infection): 1 person, 2.56%
  8. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 2.56%
  9. C-Reactive Protein Increased: 1 person, 2.56%
  10. Clostridial Infection (infectious conditions by clostridium bacteria): 1 person, 2.56%

What are the existing conditions these people have? *

  1. High Blood Pressure: 28 people, 71.79%
  2. Cardiac Failure: 21 people, 53.85%
  3. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 10.26%
  4. Type 2 Diabetes: 2 people, 5.13%
  5. Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 5.13%
  6. Weight Loss: 1 person, 2.56%
  7. Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Levothyroxine sodium and have Bladder transitional cell carcinoma?

- Check whether Bladder transitional cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Levothyroxine sodium:

Bladder transitional cell carcinoma treatments and more:

How severe was Bladder transitional cell carcinoma and when was it recovered:

Expand to all the drugs that have ingredients of levothyroxine sodium:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Levothyroxine sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bladder transitional cell carcinoma:

Browse all the conditions that are associated with Bladder transitional cell carcinoma:

How the study uses the data?

The study uses data from the FDA. It is based on levothyroxine sodium (the active ingredients of Levothyroxine sodium) and Levothyroxine sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.